Press release
Pulmonary Fibrosis Clinical, Companies, Therapy Assessment, Therapies, Treatment, Pipeline | Bristol-Myers Squibb, PureTech Health, Sarepta Therapeutics, Boehringer Ingelheim, Avalyn Pharma, Wuhan Opt
pulmonary fibrosis pipeline insights
Pulmonary Fibrosis Pipeline constitutes 110+ key companies continuously working towards developing 140+ Pulmonary Fibrosis treatment therapies, analyzes DelveInsight.
Pulmonary Fibrosis Overview:
Pulmonary fibrosis (PF) is a chronic, progressive lung disease characterized by the thickening and scarring (fibrosis) of lung tissue, particularly the interstitium, the area surrounding the air sacs (alveoli). This scarring leads to stiffening of the lungs, reducing their ability to transport oxygen into the bloodstream and making it increasingly difficult to breathe.
Request for a detailed insights report on Pulmonary Fibrosis pipeline insights [https://www.delveinsight.com/report-store/pulmonary-fibrosis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
"Pulmonary Fibrosis Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Pulmonary Fibrosis Therapeutics Market.
Key Takeaways from the Pulmonary Fibrosis Pipeline Report
*
DelveInsight's Pulmonary Fibrosis pipeline report depicts a robust space with 110+ active players working to develop 140+ pipeline therapies for Pulmonary Fibrosis treatment.
*
On October 7, 2025, the JASCAYD Registered (active ingredient: nerandomilast) tablets were approved by the Food & Drug Administration (FDA) for the treatment of Idiopathic Pulmonary Fibrosis (IPF).
*
Key Pulmonary Fibrosis companies such as Wuhan Optics Valley Vcanbiopharma Co., Ltd. Sarepta Therapeutics, Avalyn Pharma, PureTech Health, Bristol-Myers Squibb, and others are evaluating new drugs for Pulmonary Fibrosis to improve the treatment landscape.
*
Promising Pulmonary Fibrosis pipeline therapies in various stages of development include BMS-986278, LYT-100, AP01, ARO-MMP7, VUM02, and others.
Pulmonary Fibrosis Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the key companies that are developing therapies in the Pulmonary Fibrosis Market.
*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pulmonary Fibrosis treatment.
*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Pulmonary Fibrosis market.
Download our free sample page report on Pulmonary Fibrosis pipeline insights [https://www.delveinsight.com/sample-request/pulmonary-fibrosis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Pulmonary Fibrosis Emerging Drugs
*
BMS-986278: Bristol-Myers Squibb
BMS-986278 is an investigational, first-in-class oral small molecule that acts as a lysophosphatidic acid receptor 1 (LPA1) antagonist, being developed as a novel antifibrotic therapy for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). Elevated LPA levels and LPA1 activation are known to play key roles in the development of pulmonary fibrosis. BMS-986278 functions as a potent and comprehensive blocker of LPA1-mediated Gi, Gq, G12, and -arrestin signaling pathways in both engineered human cell systems and primary human lung fibroblasts. The therapy is currently in Phase III clinical trials for pulmonary fibrosis.
*
LYT-100: PureTech Health
LYT-100 (deupirfenidone) is being developed for the treatment of idiopathic pulmonary fibrosis (IPF), a rare, progressive, and life-threatening lung disease. As a deuterated version of pirfenidone, LYT-100 is designed to preserve the proven therapeutic benefits of pirfenidone while offering a distinct and improved pharmacokinetic (PK) profile. Across several clinical trials, the drug has shown enhanced tolerability, potentially supporting longer treatment duration and improved disease management. LYT-100 is currently in Phase II clinical trials for pulmonary fibrosis.
*
AP01: Avalyn Pharma
AP01, developed by Avalyn Pharma, is a novel inhaled formulation of pirfenidone intended for the treatment of pulmonary fibrosis, including idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). This inhaled version is designed to improve therapeutic effectiveness and reduce systemic side effects commonly seen with oral pirfenidone. The candidate is currently in Phase II clinical trials for pulmonary fibrosis.
*
ARO-MMP7: Sarepta Therapeutics
ARO-MMP7 is an investigational RNA interference (RNAi) therapy developed by Arrowhead Pharmaceuticals for the treatment of idiopathic pulmonary fibrosis (IPF). It works by silencing the expression of matrix metalloproteinase 7 (MMP7), a protein associated with inflammation and fibrotic tissue remodeling in the lungs. The candidate is currently being evaluated in Phase I/II clinical trials for pulmonary fibrosis.
Pulmonary Fibrosis Companies
Over 110 key companies are actively developing therapies for Pulmonary Fibrosis. Among them, Bristol-Myers Squibb has a drug candidate that has reached the most advanced stage of development-Phase III clinical trials.
DelveInsight's report covers around 75+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
Pulmonary Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Pulmonary Fibrosis Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Pulmonary Fibrosis Therapies and Key Companies: Pulmonary Fibrosis Clinical Trials and advancements [https://www.delveinsight.com/report-store/pulmonary-fibrosis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Pulmonary Fibrosis Pipeline Therapeutic Assessment
- Pulmonary Fibrosis Assessment by Product Type
- Pulmonary Fibrosis By Stage
- Pulmonary Fibrosis Assessment by Route of Administration
- Pulmonary Fibrosis Assessment by Molecule Type
Download Pulmonary Fibrosis Sample report to know in detail about the Pulmonary Fibrosis treatment market @ Pulmonary Fibrosis Therapeutic Assessment [https://www.delveinsight.com/sample-request/pulmonary-fibrosis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Pulmonary Fibrosis Current Treatment Patterns
4. Pulmonary Fibrosis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Pulmonary Fibrosis Late-Stage Products (Phase-III)
7. Pulmonary Fibrosis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Pulmonary Fibrosis Discontinued Products
13. Pulmonary Fibrosis Product Profiles
14. Pulmonary Fibrosis Key Companies
15. Pulmonary Fibrosis Key Products
16. Dormant and Discontinued Products
17. Pulmonary Fibrosis Unmet Needs
18. Pulmonary Fibrosis Future Perspectives
19. Pulmonary Fibrosis Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Pulmonary Fibrosis Pipeline Reports Offerings [https://www.delveinsight.com/report-store/pulmonary-fibrosis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=pulmonary-fibrosis-clinical-companies-therapy-assessment-therapies-treatment-pipeline-bristolmyers-squibb-puretech-health-sarepta-therapeutics-boehringer-ingelheim-avalyn-pharma-wuhan-opt]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pulmonary Fibrosis Clinical, Companies, Therapy Assessment, Therapies, Treatment, Pipeline | Bristol-Myers Squibb, PureTech Health, Sarepta Therapeutics, Boehringer Ingelheim, Avalyn Pharma, Wuhan Opt here
News-ID: 4241455 • Views: …
More Releases from ABNewswire
Oral Surgeon Huntington Beach Practice Elevates Standards for Patient Comfort an …
Huntington Beach oral surgery practice, The Wisdom Teeth Guru sets new patient care standards through specialized training, advanced sedation options, and efficient same-day treatment capabilities under Dr. Kiet Tran's leadership.
A Huntington Beach dental practice has gained recognition for transforming how patients experience oral surgery procedures. The Wisdom Teeth Guru [https://www.google.com/maps/place/The+Wisdom+Teeth+Guru/data=!4m2!3m1!1s0x0:0x98592ab69d239d3a?sa=X&ved=1t:2428&hl=en&ictx=111], led by Dr. Kiet Tran, has established new benchmarks in patient care through advanced techniques and a commitment to making…
Columbus Moving Services Expands as Moving Ahead Services Responds to Central Oh …
Moving Ahead Services expands coverage across 23 Central Ohio communities, offering flexible moving solutions with regulatory compliance and community partnerships that support both residential and commercial relocations.
The Central Ohio region continues to experience steady population growth, and Moving Ahead Services has positioned itself to address the increasing demand for professional relocation assistance. The expansion of Columbus moving services reflects the company's two decades of experience serving the area, with operations…
What Does a Full-Service Move Include? Moving Companies Report Surge in Demand f …
Greenville homeowners increasingly prefer comprehensive relocation packages that handle packing, furniture assembly, transportation, and setup. Professional services reduce stress and damage while streamlining transitions.
Homeowners and renters across Greenville are opting for comprehensive relocation packages as the complexity of modern moves continues to grow. Recent trends show that families and businesses alike are seeking moving companies for an end-to-end solution that eliminates the stress traditionally associated with changing addresses. This shift…
Local Garage Door Company Sees Surge in Emergency Repairs Following Extreme Temp …
AA Garage Door LLC reports increased emergency repairs across St. Paul as extreme cold causes cable failures and spring breaks. Technicians respond to urgent service needs throughout Twin Cities neighborhoods affected by harsh winter conditions.
Recent weather patterns across the St. Paul region have created unprecedented challenges for homeowners, with plummeting temperatures causing significant strain on residential overhead door systems. AA Garage Door LLC, a trusted garage door company [https://maps.google.com/maps?ll=44.91738,-93.190993&z=16&t=h&hl=en&gl=PH&mapclient=embed&cid=15111651982362415047&q=garage+door+company&oq=garage+door+company+near+me] serving…
More Releases for Pulmonary
Innovation In Pulmonary Drug Delivery Devices Industry Trends Gaining Momentum i …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Pulmonary Drug Delivery Devices Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for pulmonary drug delivery devices has experienced significant growth in the past few years. The market is projected to increase from $49.52 billion in 2024 to $52.8 billion in 2025,…
Chronic Pulmonary Aspergillosis Drugs Market - Revitalizing Lungs: Revolutionary …
Newark, New Castle, USA - new report, titled Chronic Pulmonary Aspergillosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Pulmonary Aspergillosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Pulmonary Aspergillosis Drugs market. The report offers…
Global Pulmonary Arterial Hypertension Market Size
According to a new market research report published by Global Market Estimates, the Global Pulmonary Arterial Hypertension Market is projected to grow at a CAGR of 5.2% from 2022 to 2027.
Congenital heart diseases and other ailments such as HIV infection, chronic liver disease (cirrhosis), and connective tissue disorders (scleroderma, lupus, and others) are fueling market expansion.
Browse 153 Market Data Tables and 113 Figures spread through 185 Pages and in-depth TOC…
New Study: Pulmonary Drugs Market Report
The pulmonary drugs market is expected to witness unprecedented growth in the near future, thanks to large number of approvals from the FDA. The FDA approved a large number of pulmonary drugs for major illnesses like small-cell lung cancer, tuberculosis, and pneumonia over the past few years. Additionally, newly approved drugs also treat newly found diseases like obstructive sleep apnea. These approvals are in line with the recent trend of…
Pulmonary Drugs Market Forecast till 2025
Pulmonary Drugs Market – Boon for Diseased Lungs
Pulmonary drugs can treat wide range of conditions, which are included within the ambit of pulmonary diseases such as pneumonia, allergic rhinitis, pulmonary hypertension, and others. . Pulmonary drugs provide medications for all types of pulmonary diseases, which is expected to fuel market growth in near future. The World Health Organization (WHO) states that most respiratory diseases are preventable and can be treated…
Pulmonary Drug Delivery Devices Market: Demand for Pulmonary Drug Delivery Devic …
This report on pulmonary drug delivery devices studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of various pulmonary/respiratory drugs and/or drug-device combinations as well as new entrants planning to enter this market.
This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments…
